deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00783367

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Follicular Lymphoma Lymphoma of Mucosa-Associated Lymphoid Tissue Lymphoma, Small Lymphocytic MALT Lymphoma Mantle-Cell Lymphoma Marginal Zone B-Cell Lymphoma Waldenstrom Macroglobulinemia
Interventions Dexamethasone Lenalidomide Rituximab
Updated 15 times since 2017 Last updated: Mar 28, 2023 Started: Jul 31, 2008 Primary completion: Nov 14, 2012 Completion: Nov 23, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Follicular Lymphoma and Lymphoma of Mucosa-Associated Lymphoid Tissue, this trial is completed. The trial is conducted by Abramson Cancer Center at Penn Medicine and has accumulated 15 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Apr 2020 · 11 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jul 2022 · 13 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Jan 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 10 earlier versions

  1. Jul 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  4. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  6. May 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown Status → Active Not Recruiting

  7. Feb 2019 — May 2019 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  8. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations